PAS
MDGL icon

Park Avenue Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Park Avenue Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Sell
639
-162
-20% -$83K ﹤0.01% 1455
2026
Q1 		$419K Sell
801
-57
-7% -$27.2K ﹤0.01% 1183
2025
Q4 		$499K Buy
858
+72
+9% +$36.8K ﹤0.01% 1089
2025
Q3 		$360K Buy
786
+87
+12% +$32.5K ﹤0.01% 1338
2025
Q2 		$212K Buy
699
+43
+7% +$12.8K ﹤0.01% 1416
2025
Q1 		$217K Buy
+656
New +$216K ﹤0.01% 1107

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Park Avenue Securities's MDGL Position: Q2 2026 in Review

Park Avenue Securities reduced its Madrigal Pharmaceuticals (MDGL) stake by 20% in Q2 2026, selling an estimated $83K and leaving 639 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1455.

Park Avenue Securities first reported a position in MDGL in Q1 2025 and has held it in 6 quarters since. The position peaked at $499K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Park Avenue Securities held 639 shares of Madrigal Pharmaceuticals worth $343K as of Q2 2026.
  • Park Avenue Securities sold 162 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $83K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1455 holding.
  • Park Avenue Securities first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Park Avenue Securities's Madrigal Pharmaceuticals position peaked at $499K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.